Table 4 Liver function parameters of the whole patient cohort before and one day after TACE procedure
From: TACE performed in patients with a single nodule of Hepatocellular Carcinoma
Variable | Pre-TACE | Post-TACE | P |
|---|---|---|---|
Ascites, n (%) | 0.564 | ||
Absent | 120 (81) | 116 (78) | |
Present | 28 (19) | 32 (22) | |
Encephalopathy, n (%) | 1.000 | ||
Absent | 145 (98) | 145 (98) | |
Slight | 3 (2) | 3 (2) | |
Serum total bilirubin, median (mg/dL) (range) | 1.34 (0.30 – 10.67) | 1.85 (0.30 – 13.94) | <0.001 |
Serum albumin, median (g/dL) (range) | 3.60 (2.10 – 5.00) | 3.50 (2.10 – 4.50) | <0.001 |
Serum creatinine, median (range) | 0.92 (0.50 – 1.73) | 0.97 (0.57 – 2.27) | 0.823 |
Hepatic function, n (%) | 0.010 | ||
CPT-A | 92 (62) | 81 (55) | |
CPT-B | 56 (38) | 61 (41) | |
CPT-C | 0 | 6 (4) | |
Hepatic function, n (%) | 0.054 | ||
CPT-A5 | 65 (44) | 53 (36) | |
CPT-A6 | 27 (18) | 27 (18) | |
CPT-B7 | 28 (19) | 26 (18) | |
CPT-B8 | 21 (14) | 25 (17) | |
CPT-B9 | 7 (5) | 11 (7) | |
CPT-C10 | 0 | 6 (4) | |
Serum INR, median (range) | 1.28 (1.00 – 1.97) | 1.33 (1.00 – 2.00) | 0.003 |
MELD score, median (range) | 11 (6 – 24) | 12 (7 –24) | <0.001 |